Cultural flair of San Francisco is unmatched worldwide
March 1st 2009San Francisco is nearly synonymous with a high cost of living. The advent and financial success of the early years of the Internet revolution still lures high-income folks to the city by the bay. Property values and household income are among the top in the nation, which enables a profitable restaurant and entertainment scene.
For dry eye patients punctal plugs offer flow control
March 1st 2009Soft Plug Flow Control Silicone Plugs (Oasis Medical) provide partial occlusion of the puncta with limited tear drainage for patients with moderate and severe dry eye. These plugs eliminate epiphora in patients for whom total occlusion is excessive.
Corneal topography stability after crosslinking is demonstrated by comprehensive analyses
March 1st 2009Results from visual acuity testing, refraction, and corneal topography analysis using Scheimpflug imaging (Pentacam, Oculus) in a series of 48 eyes with progressive keratoconus demonstrate the benefits of corneal collagen crosslinking for halting keratoconus progression. More research is needed to provide answers to questions about the long-term stability of collagen corneal crosslinking and to refine its indications and contraindications.
Eye-care position receives new classification
March 1st 2009The Joint Commission on Allied Health Personnel in Ophthalmology announced in a prepared statement that it has received approval for a separate occupational classification, ophthalmic medical technician, from the U.S. Bureau of Labor's 2010 Standard Occupational Classification committee.
Dyax, Fovea enter into license agreement
March 1st 2009Dyax Corp. and Fovea Pharmaceuticals have entered into an exclusive license agreement for the development and commercialization of an ocular formulation of DX-88 for the treatment of retinal diseases, the companies announced in a joint statement.
Roche attempts hostile takeover
March 1st 2009Analysts and ophthalmologists are closely watching the drama unfolding between private Swiss drugmaker Roche and the publicly traded, California-based Genentech, maker of ranibizumab (Lucentis), the only FDA-approved treatment for age-related macular degeneration (AMD), and its popular cousin, bevacizumab (Avastin). Roche is attempting a hostile takeover of Genentech.
Implementing an electronic prescribing system
February 27th 2009This is the personal experience of electronic prescribing (e-prescribing) implementation presented by Cindy Maddox, MD, FACS, director of glaucoma services and vice chairwoman at the New England Eye Center, Tufts University School of Medicine, Boston and member of the American Academy of Ophthalmology's health policy committee.
People with astigmatism are unaware of contact lens options, says survey
February 24th 2009A survey conducted by independent research firm, Decision Analyst, and sponsored by Bausch & Lomb, found that four out of 10 consumers incorrectly believe that their astigmatism prevents them from wearing contact lenses.
Mumbai Eye Care Campaign launched to prevent blindness
February 24th 2009Sightsavers International has launched the Mumbai Eye Care Campaign to prevent avoidable blindness and to offer eye care to millions of Mumbai's citizens in underserved areas of the city, such as Dharavi, the setting of the award-winning film, 'Slumdog Millionaire.'
Eye-care position receives new classification in occupational listing
February 18th 2009The Standard Occupational Classification listing encompasses all three levels of JCAHPO certification: certified ophthalmic assistant, certified ophthalmic technician, and certified ophthalmic medical technologist, the organization said.
Pfizer to disclose compensation of U.S. health-care professionals, others
February 18th 2009Pfizer will disclose publicly its compensation of U.S. health-care professionals for consulting, speaking engagements, and clinical trials by early next year on the company’s Web site, according to a prepared statement from the company.
Dyax and Fovea enter into license agreement
February 18th 2009Dyax Corp. and Fovea Pharmaceuticals announced in a joint statement that they have entered into an exclusive license agreement for the development and commercialization of an ocular formulation of DX-88 for the treatment of retinal diseases.
Tear film rebuilding is goal of drop
February 15th 2009A new formulation of lubricant eye drop (Systane Ultra, Alcon Laboratories) contains polymer network and demulcent ingredients that have been proven in multiple studies to provide benefits in patients with dry eye disease, according to one ophthalmologist. The drop, however, reformulates these agents in a system designed to further enhance ocular surface comfort, protection, and symptomatic relief. Initial patient impressions are very positive, he said.
Tear formulations unique in dry eye therapy, management
February 15th 2009Blink GelTears and Blink Tears Preservative-Free (Advanced Medical Optics) are two new over-the-counter products for the treatment of dry eye disease. These products are gaining in popularity with ophthalmologist because of the rapid long-lasting beneficial response they produce in this patient population and the absence of a preservative. The products are also beneficial for patients who have undergone LASIK and cataract surgery and develop subsequent dry eye signs and symptoms postoperatively.
Use technology to improve your contact lens practice
February 15th 2009Contact lens practices are probably feeling the effects of more and more patients simply taking their prescriptions and buying their lenses on the Internet. But, if contact lens fitting is a valuable service that you offer and you want to improve your productivity and profitability, then you might want to make a few changes. Using the Internet to send email updates to patients, ordering supplies online, and giving patients the option to purchase on your Web store will make a big difference in your practice.
Category III codes provide key to new technologies
February 15th 2009Ophthalmologists are well acquainted with the Current Procedural Terminology (CPT), but many ophthalmologists are only familiar with CPT's "Category I" codes. It is important for ophthalmologists to understand code Category III, since many eye-care services have appeared or will appear in this category.